Fostemsavir Tromethamine
1 NDC across 1 manufacturer|0 Generic,1 Brand
Fostemsavir Tromethamine is used to treat HIV infections, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 2, 2020. In 2024, Medicare Part D spent $115 million on Fostemsavir Tromethamine across 13,000 claims for 1,505 beneficiaries.
Fostemsavir Tromethamine is available as 1 NDC from 1 manufacturer (0 generic, 1 brand), with NADAC prices from $156.84 to $156.84 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
1
0G / 1B
Manufacturers
1
competing in market
Price Spread
$156.84 – $156.84
per EA
7d Activity
avg +0.0% WoW · of 1 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
1 manufacturer producing FOSTEMSAVIR TROMETHAMINE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
RUKOBIA ER 600 MG TABLET | $156.8362 per EA | 0.00% |
Frequently Asked Questions
What is Fostemsavir Tromethamine used to treat?
Fostemsavir Tromethamine is used to treat HIV infections, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Fostemsavir Tromethamine?
In 2024, Medicare Part D spent $115 million on Fostemsavir Tromethamine across 13,000 claims for 1,505 beneficiaries.
How many Fostemsavir Tromethamine products are on the market?
The Fostemsavir Tromethamine drug market contains 1 NDC from 1 manufacturer — 0 generic and 1 brand product.
What is the price range for Fostemsavir Tromethamine?
NADAC reference prices for Fostemsavir Tromethamine range from $156.8362 to $156.8362 per EA.
Which manufacturers make Fostemsavir Tromethamine?
1 manufacturer lists Fostemsavir Tromethamine in NADAC. Ranked by number of NDCs, the largest are ViiV Healthcare Company (1).
How has the price of Fostemsavir Tromethamine changed recently?
Over the past 7 days, 0 Fostemsavir Tromethamine NDCs rose and 0 fell, with a market-wide average change of +0.0%.